Global pharma major Lupin Limited (Lupin) today announced that it has received approval for its Sevelamer Hydrochloride Tablets, 400 mg and 800 mg from the United States Food and Drug Administration to market a generic equivalent of Renagel® Tablets, 400 mg and 800 mg, of Genzyme Corporation. The product will be manufactured at Lupin's facility in Nagpur, India.
Sevelamer Hydrochloride Tablets are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.
Sevelamer Hydrochloride Tablets (RLD: Renagel®) had estimated annual sales of USD 80 million in the U.S. (IQVIA MAT March 2021).
Shares of LUPIN LTD. was last trading in BSE at Rs.1176.85 as compared to the previous close of Rs. 1186.65. The total number of shares traded during the day was 150661 in over 4862 trades.
The stock hit an intraday high of Rs. 1197 and intraday low of 1173.95. The net turnover during the day was Rs. 178180131.